KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Recursion Pharmaceuticals (RXRX) Accumulated Depreciation & Amortization: 2022-2024

Historic Accumulated Depreciation & Amortization for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Dec 2024 value amounting to $13.0 million.

  • Recursion Pharmaceuticals' Accumulated Depreciation & Amortization rose 71.47% to $13.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $36.5 million, marking a year-over-year increase of 49.55%. This contributed to the annual value of $36.5 million for FY2024, which is 49.55% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Accumulated Depreciation & Amortization of $13.0 million as of Q4 2024, which was up 79.92% from $7.2 million recorded in Q3 2024.
  • Recursion Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $30.1 million for Q4 2022, and its period low was $2.8 million during Q1 2022.
  • For the 3-year period, Recursion Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $9.4 million, with its median value being $7.5 million (2023).
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first crashed by 74.92% in 2023, then surged by 97.88% in 2024.
  • Quarterly analysis of 3 years shows Recursion Pharmaceuticals' Accumulated Depreciation & Amortization stood at $30.1 million in 2022, then crashed by 74.92% to $7.6 million in 2023, then spiked by 71.47% to $13.0 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $13.0 million for Q4 2024, versus $7.2 million for Q3 2024 and $9.0 million for Q2 2024.